G LP ‐1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea
Obesity · 2024
DOI: 10.1002/oby.24126 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Obesity, 2024. Verfasst von Cliona O'Donnell und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary and Sleep Disorders Unit, St. Vincent's University Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Sleep Apnea, Obstructive, Intra-Abdominal Fat, Continuous Positive Airway Pressure, Glucagon-Like Peptide 1. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Health Research Board of Ireland, Health Research Board.
Abstract (Originalsprache)
Objective
Glucagon‐like peptide‐1 (GLP‐1) analogues are currently the most widely used pharmacotherapies for weight loss. Their primary mechanism of action is attributed to reduction in energy intake. Data from murine studies also support an additional impact of those agents on energy homeostasis through upregulation of visceral adipose tissue (VAT) metabolic activity, but this remains uncertain in humans.
Methods
Here, we present data from a proof‐of‐concept study on 30 individuals with obstructive sleep apnea and obesity who were randomized to a GLP‐1 therapy‐based weight loss regimen, continuous positive airway pressure, or a combination of both for 24 weeks. At baseline and study completion, 18F‐fluorodeoxyglucose (18F‐FDG) positron emission tomography‐computed tomography (PET‐CT) was performed to evaluate VAT metabolic activity, expressed as VAT target to background ratio.
Results
Treatment with GLP‐1, but not with continuous positive airway pressure, was associated with a significant increase in VAT target to background ratio. There was a strong correlation between the increase in VAT metabolic activity and the degree of weight loss.
Conclusions
These data support the hypothesis that upregulation of VAT metabolic activity by GLP‐1 contributes to its weight loss action in humans, and this subject warrants further detailed investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pulmonary and Sleep Disorders Unit, St. Vincent's University Hospital, Dublin, Ireland.
- School of Medicine, University College Dublin, Dublin, Ireland.
- Department of Endocrinology, St. Vincent's University Hospital, Dublin, Ireland.
- St. Columcille's Hospital, Dublin, Ireland.
- Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, Ireland.
- Department of Radiology, St. Vincent's University Hospital, Dublin, Ireland.
ORCID-Profile: Andrew E Hogan
Förderung
- Health Research Board of Ireland
- Health Research Board
Zitieren
APA
O'Donnell, C., Ryan, O., Hogan, A. E., Killick, D., Crilly, S., Dodd, J. D., Murphy, D. J., Ryan, S., & O'Shea, D. (2024). G LP ‐1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea. Obesity. https://doi.org/10.1002/oby.24126
Vancouver
O'Donnell C, Ryan O, Hogan AE, Killick D, Crilly S, Dodd JD, et al. G LP ‐1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea. Obesity. 2024. doi:10.1002/oby.24126
BibTeX
@article{ODonnell2024,
author = {O'Donnell, Cliona and Ryan, Odhrán and Hogan, Andrew E and Killick, Desmond and Crilly, Shane and Dodd, Jonathan D and Murphy, David J and Ryan, Silke and O'Shea, Donal},
title = {G LP ‐1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea},
journal = {Obesity},
year = {2024},
doi = {10.1002/oby.24126}
}
EUVIMED